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Abstract: Dysbiosis is associated with acute and long-term consequences for neonates. Probiotics can
be effective in limiting the growth of bacteria associated with dysbiosis and promoting the healthy
development of the infant microbiome. Given its adaptation to the infant gut, and promising data
from animal and in vitro models, Bifidobacterium longum subsp. infantis is an attractive candidate for
use in infant probiotics. However, strain-level differences in the ability of commercialized strains to
utilize human milk oligosaccharides (HMOs) may have implications in the performance of strains
in the infant gut. In this study, we characterized twelve B. infantis probiotic strains and identified
two main variants in one of the HMO utilization gene clusters. Some strains possessed the full
repertoire of HMO utilization genes (H5-positive strains), while H5-negative strains lack an ABC-type
transporter known to bind core HMO structures. H5-positive strains achieved significantly superior
growth on lacto-N-tetraose and lacto-N-neotetraose. In vitro, H5-positive strains had a significant
fitness advantage over H5-negative strains, which was also observed in vivo in breastfed infants.
This work provides evidence of the functional implications of genetic differences among B. infantis
strains and highlights that genotype and HMO utilization phenotype should be considered when
selecting a strain for probiotic use in infants.
Keywords: gut microbiome; dysbiosis; probiotics; HMO; NEC

1. Introduction
Hospitalization, surgical birth, antibiotic exposure, and many routine perinatal interventions are
known to have detrimental effects on the gut microbiome, resulting in dysbiosis [1]. If unresolved,
the negative effects of dysbiosis can be acute and/or long lasting [2,3]. Dysbiosis is linked to the
pathogenesis of common neonatal conditions including necrotizing enterocolitis (NEC) and sepsis [4]
as well as the development of autoimmune diseases later in life [2,3]. Human milk has been linked to
improved infant outcomes with respect to acute and long-term disease risk. These benefits are in part
provided by favoring the growth of specific beneficial bifidobacteria capable of consuming human
milk oligosaccharides (HMOs) [5].
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HMOs are indigestible by the infant, yet they are the third most abundant component in human
milk, reaching nearly 20 g/L in colostrum and between 5 and 15 g/L in mature milk [6,7]. Structurally,
all HMOs follow common blueprints, which consist of a lactose moiety decorated with either fucose or
sialic acid or elongated by a β-1-3/6-linked lacto-N-biose (LNT) or lacto-N-tetrose (LNnT) to derive
type-1 and type-2 core structures, respectively. These core structures can be further elongated with
residues of galactose, N-acetylglucosamine, and decorated with fucose or sialic acid [8]. These type-1
and type-2 cores are found in HMO structures representing ~70% of the total HMO concentration
in women that express the fucosyl transferase FUT2, known as “secretors” (FUT2+/+ or FUT2+/− )
and over 90% of the total HMO content in “non-secretors” (FUT2−/− ) [7]. Notably, type-1 HMOs
consistently predominate over type-2 HMOs (LNnT core), a trait that appears to be characteristic of
human milk [7,9–11].
Infant-adapted bifidobacteria have evolved different strategies to assimilate HMOs. Bifidobacterium
breve and Bifidobacterium bifidum deploy the extracellular enzymes and engage in inter- and intra-species
tropic networks to sequentially degrade HMOs [12,13]. In contrast, Bifidobacterium longum subsp.
infantis (B. infantis) metabolizes HMOs intracellularly. Accordingly, the genome of B. infantis encodes
an assortment of genes dedicated to the transport and the intracellular metabolism of HMOs, organized
in five gene clusters (H1 to H5) [14], including a contiguous 40 kb cluster (H1) that appears to be
conserved amongst all B. infantis genomes examined so far [15,16]. Studies using the type strain ATCC
15697 revealed that HMOs are selectively bound through specific extracellular solute binding proteins
(F1SBP) and imported into the cell using ABC-type transporters [12,13]. Once internalized, HMOs are
hydrolyzed into their monosaccharide components and metabolized via the “bifid shunt” pathway,
producing mainly lactate and acetate as fermentation end products [17–19]. This transporter-dependent
intracellular consumption strategy enables B. infantis to efficiently capture preferred carbon sources in
the competitive ecosystem of the gut and lowers the intestinal pH through the production of organic
acids, which can inhibit the growth of competitors [13,20–23].
Genotypic variation within HMO utilization gene clusters have been documented across B. longum
subspecies [15]. However, the functional and ecological implications of strain-level differences among
commercialized strains have not been explored in detail. The objective of this study was to assess
genomic variation among various B. infantis isolates, obtained from commercially available probiotic
products, by performing a comparative analysis of their genomes. We then determined how the
presence or absence of key genes involved in HMO utilization affected the growth of these strains in vitro.
Finally, in a proof-of-concept experiment, we examined the stool samples of breastfed infants who were
fed an H5-positive B. infantis probiotic strain (replete with the full gene repertoire of HMO-utilization
genes) and an H5-negative B. infantis probiotic strain (deplete of an ABC-type transporter in the
H5-cluster), in order to measure the relative abundance of each strain recovered in the stool samples.
2. Materials and Methods
2.1. Bacterial Strains and Culture Conditions
Bacterial strains used in this study (Table 1) were isolated from commercial probiotic products or
obtained from the American Type Culture Collection (ATCC.org). Briefly, probiotic products were
homogenized, diluted and cultured in Bifidobacterium selective iodoacetate mupirocin (BSIM) media
prepared as described by Lewis et al. (2016) [24]. Plates were incubated at 37 ◦ C in an anaerobic
chamber maintained with a gas mix of 5% H2 , 5% CO2 , and 90% N2 (Coy Laboratory Products,
Grass Lake, MI, USA) for 48–72 h until distinguishable colonies were formed. Resulting colonies were
streaked onto BSIM agar and, after two passages, were grown in MRS broth supplemented with 0.05%
L-cysteine HCl. The identity of 10 randomly selected colonies per product was determined using
Sanger sequencing of the species-variable Internal Transcribed Spacer region within the rRNA locus,
housed between the 16S and 23S rRNA genes, using the forward 50 -CTKTTGGGYYCCCKGRYYG-30
and reverse 50 -CGCGTCCACTMTCCAGTTCTC-30 primers [25]. For products with multiple strains
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of Bifidobacterium, a selective HMO-modified MRS (hmMRS) agar medium was devised to contain
(per liter) 2 g of ammonium citrate, 10 g of tryptone, 2 g of dipotassium phosphate, 0.2 g of magnesium
sulfate, 0.05 g of manganese sulfate and 0.5 g of L-cysteine HCL. The 20 -FL solutions (100 g/L) were
prepared in distilled water and sterilized by filtration (0.2 µM) and added to autoclaved mMRS to a
final 20 -FL concentration of 20 g/L. Strains isolated through this method were confirmed as B. infantis
using subspecies-specific qPCR as described by Lawley et al. (2017) [26]. Confirmed B. infantis strains
were stored at −80 ◦ C in MRS containing 15% glycerol. Inocula for growth experiments were prepared
by growing individual strains overnight in MRS broth, followed by subculture (with 1% inoculum) in
fresh mMRS + 0.5% L-cysteine HCL for 16 h.
Table 1. General features of the bifidobacteria included in this study.

Group

Strain

Source
Reference/
Source

NCBI
Accession
Number

Size
(Kbp)

Coverage (x)

GC (%)

CDSs

tRNAs

1

ATCC
15697

Sela (2008)
sela [14]

NC_011593

2832

n/a

59.8

2547

84

1

JCM 1222

Fukuda
(2011)
Fukuda [20]

NC_017219

2828

n/a

59.8

2544

84

1

EVC001

probiotic
product

NZ_LR655210 2832

147

59.8

2553

84

2

NLS

probiotic
product

CP054528

2598

332

59.3

2226

59

2

BB-02
(DSM33361)

probiotic
product

CP054527

2758

486

59.8

2437

60

2

PI_002

probiotic
product

CP054526

2604

185

59.3

2227

59

2

HA-116

probiotic
product

CP054525

2612

88

59.2

2232

59

2

PI_004

probiotic
product

CP054524

2604

172

59.3

2226

59

2

R0033x

probiotic
product “x”

CP054523

2614

130

59.2

2233

59

2

R0033y

probiotic
product “y”

CP054596

2615

171

59.2

2234

59

2

PI_007

probiotic
product

CP054522

2604

220

59.3

2228

59

2

PI_008

probiotic
product

CP054521

2612

213

59.2

2230

59

2

PI_009

probiotic
product

CP054520

2604

162

59.3

2230

59

2

PI_010

probiotic
product

CP054519

2609

117

59.2

2231

59

NCBI: National Center for Biotechnology Informatio; %GC: percent of guanuce-cytosine; CDs: Coding Sequences;
tRNAs: Transfer RNAs; n/a: not applicable.

2.2. Whole-Genome Sequencing Assembly and Annotation
High-molecular-weight (>30 Kb) DNA was extracted from B. infantis strains using the MasterPure
Gram-Positive DNA Purification Kit (Epicentre, Madison, WI, USA) following the manufacturer’s
instructions with an additional lysis step including achromopeptidase (5 U/µL) in conjunction with
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lysozyme. Extracted DNA was quantified using the Quant-iT™ dsDNA High-Sensitivity Kit (Invitrogen)
and checked for integrity in a 1% agarose gel.
Genome sequences were generated by a combination of paired-end Illumina reads and MinION or
PacBio long reads. Multiplexed short-read libraries were prepared for all strains excluding BB-02 (DSM
33361) using the Nextera XT Library preparation kit (Illumina, San Diego, CA, USA) and sequences were
determined using a 2 × 300 paired-end Illumina MiSeq run at the University of California Davis DNA
Technologies Core Facility. A library was prepared for the BB-02 (DSM 33361) strain with NEBNext®
Ultra™ DNA Library Prep Kit for Illumina (New England BioLabs, Ipswich, MA, USA) and sequenced
with a 2 × 300 paired-end run on an Illumina MiSeq (Illumina, San Diego, CA, USA) by GENEWIZ
(South Plainfield, NJ). To generate Oxford Nanopore long reads, the Rapid Barcoding kit (SQK-RBK004;
Oxford Nanopore, Oxford UK) was used to prepare barcoded libraries according to the manufacturer’s
instructions. The sequencing library was loaded into the flow cell (R9.4.1). A 6 h sequencing protocol
was selected on the MinKNOW control software. PacBio sequencing was performed at the Vincent
J. Coates Genomics Sequencing Laboratory at the University of California, Berkeley using a Pacific
Biosciences RSII sequencer (Pacific Biosciences, Menlo Park, CA, USA). Bacterial genome assemblies
were carried out using a hybrid assembly approach combining PacBio or MinION long reads with
Illumina reads in Spades v3.11 [27] with parameters optimized for hybrid assemblies [28]. Assembled
genomes were annotated with Prokka v1.12 [29] using default parameters.
2.3. Genome-Wide Comparisons, Phylogenetic Analysis and HMO Gene Analysis
Bacterial genomes were visualized and compared using the BLAST Ring Image Generator (BRIG)
v0.95 [30]. Gene map comparisons were generated with Easyfig [31]. Average nucleotide identity was
calculated using the ANIm algorithm from pyANI v.0.2.10 [32]. The annotated genomes obtained
with Prokka were then processed with Roary version 3.11.2, [33] to identify the set of core genes (95%
protein clustering identity threshold). Unique genes identified by Roary were then manually curated
to confirm the uniqueness of genes by strain. For strains predicted to have more than 10 unique genes,
a BlastX analysis (cut off: E value of 1 × 10−4 ) was used to confirm presence of homologues in the type
strain as previously described [34].
Phylogenetic analysis for assembled genomes was performed within the Anvi’o multi-omics
platform v6.2 [35]. Protein sequences of 71 curated single-copy genes [35,36] were used for downstream
phylogenetic analysis. Homologs were aligned and concatenated with MUSCLE v3.8.1551 [37].
A phylogenetic tree was generated with FastTree v.2.1.10 [38]. The tree was rooted with an outgroup of
B. longum subsp. longum JCM 1217. HMO utilization genes protein sequences were queried against
each genome using local tBLASTn within local Blast v.2.9.0+ [39]. The phylogenetic tree with HMO
utilization gene heat map was generated in R v3.6.1 using the phylo.heatmap function within the
phytools v0.7-20 package.
2.4. Growth on HMO Standards
Probiotic strains were tested for their ability to grow in lacto-N-tetraose (LNT), lacto-N-neotetraose
(LNnT), and 20 -Fucosyllactose (20 -FL) (Glycome A/S, Hørsholm, Denmark) as the sole carbon source.
Briefly, on a modified MRS (mMRS) media to contain (per liter) 2 g of ammonium citrate, 10 g of
tryptone, 2 g of dipotassium phosphate, 0.2 g of magnesium sulfate, 0.05 g of manganese sulfate
and 0.5 g of L-cysteine HCL. Medium components were dissolved in distilled water to 80% of the
final volume and autoclaved. Individual HMO standards LNT, LNnT or 20 -FL were dissolved in
the residual volume (20%), sterilized by filtration, and added to the autoclaved medium to final
concentration of 20 g/L. Media were inoculated at 1% (v/v) using standardized 16 h cultures of each
strain. Growth profiles were monitored over 30 h by measuring optical density (OD600 ) using an
Epoch2 spectrophotometer (Biotek, Winooski, VT, USA) at 37 ◦ C, placed inside an anaerobic chamber
maintained with a gas mix of 5% H2 , 5% CO2 , and 90% N2 (Coy Laboratory Products, Grass Lake,
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MI, USA). Three biological replicates were performed for each strain. Growth curve parameters were
calculated using the Growthcurver R package v0.2.1 [40].
2.5. Purification of HMOs from Human Milk and Bacterial Growth
Purified HMOs were obtained from 50 L of human milk pooled from 11 donors kindly provided
by Medolac Laboratories (Boulder City, NV, USA) to Dr. Daniela Barile. An integrated approach for
the purification of oligosaccharides, based on optimized conditions that favor elimination of lipids,
proteins and simple sugars, was applied with minor modification to adapt the protocol from bovine
milk to human milk composition [41]. Maximum lactose hydrolysis and selective fermentation of the
resulting monosaccharide was achieved, while oligosaccharides were obtained by the sequential use of
pilot-scale membrane filtrations such as ultrafiltration, microfiltration and nanofiltration followed by
lyophilization, allowed to obtained an HMO-rich powder that was free of lipids, proteins and simple
sugars, with an HMO recovery of nearly 90%. Mono- and disaccharides and the most abundant HMOs
((60 -sialyllactose (60 -SL); 30 -sialyllactose (30 -SL); lacto-N-tetraose (LNT); lacto-N-neotetraose (LNnT),
3-fucosyllactose (30 -FL), 20 -fucosyllactose (20 -FL), and lacto-N-fucopentaose I (LNFP I)) were quantified
by using High-Performance Anion-Exchange Chromatography with Pulsed Amperometric Detection
(HPAEC-PAD, ICS-5000, Thermo Scientific, Sunnyvale, CA, USA) following previously published
procedures [42].
For growth experiments, purified HMOs were dissolved to a concentration of 10 g/L in RPMI
1640 (sans glucose) medium (Corning, Corning, NY, USA). Cultures and growth experiments were
conducted as described above.
2.6. Glycoprofiling
Bacterial cultures in mMRS medium were collected at 6 and 30 h of growth, representing the
early-log phase and the late stationary phase. Bacterial cells were removed by centrifugation at 10,000×
g for 2 min. Supernatant was collected and diluted 10,000-fold. Dilutions were filtered through
a 0.22 µm cellulose acetate membrane (VWR International, Radnor, PA, USA) and 25 µL of these
supernatants were injected into a High-Performance Anion-Exchange Chromatograph Coupled with
Pulsed Amperometric Detection instrument (HPAE-PAD ICS-5000, Thermo Scientific, Sunnyvale, CA,
USA) according to methods from [43] with some modifications. Briefly, chromatographic separation
was carried out on a CarboPac PA1 analytical column (4 × 250 mm, DionexTM, ThermoFisher Scientific,
Waltham, MA, USA) and CarboPac PA1 guard column (4 × 50 mm, Dionex) with an isocratic gradient,
0–30 min 73.5% A, 25% B, 1.5% C, at a 1.0 mL/min flow rate, where solvent A was deionized water,
solvent B 100 mM NaOH and solvent C was 500 mM NaOAc in 100 mM NaOH. HMOs were quantified
using calibration curves generated using reference standards of LNT, LNnT (Dextra, Reading, UK) and
20 -FL (Carbosynth, St. Gallen Switzerland), ranging in concentration from 0.00025 to 0.005 mg/mL.
All samples were analyzed in triplicate.
2.7. Strain-Specific Primer Development
A real-time PCR assay was developed to distinguish and quantify the abundance of the
H5-positive strain EVC001 and the H5-negative strains NLS, HA-116 and PI_008. Briefly, a reciprocal
BLASTn search was used to compare B. infantis EVC001 and H5-negative strains to identify
candidate genes containing strain-specific SNPs. The LNB phosphorylase gene (“Blon_2174” in
strain ATCC 15697) was identified as a candidate region. Primer3 [44] was used to design the forward
2174_F 50 -GATCGGTGTTGTTGATCACG-30 and reverse 2147_R 50 -CCTCCCACAACGAAGACAAG-30
primers as well as the strain-specific probes G1_probe 56-FAM/CAATACAGGCCCTGCTCG-3IABkFQ
and G2_probe 56-JOEN/CAGTACAGGCCCTGTGCG-3IABkFQ. To validate the primers, in silico PCRs
were carried out for all multiplex assays with CLC Main Workbench v.9.5.4 (CLC bio, Aarhus, Denmark)
using the ‘Find Binding Sites and Create Fragments’ tool. Specificity of the primers/probe combination
was also determined by BLASTn searches against the NCBI nr database and validated experimentally
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by combining DNA from H5-positive and H5-negative strains. No unspecific amplification was
detected. Primer/probe efficiency was calculated for each primer/probe set using five 1:10 serial
dilutions of the genomic DNA extracted from a culture for which cell numbers had been determined
by plate count.
2.8. In Vitro Competitive Assays
Competitive growth of NLS strain and EVC001 was determined by serial subculture over a 72 h
period. Three parallel cultures of each strain were initiated by transferring single colonies into 10
mL MRS medium (Difco BD, Franklin Lakes, NJ, USA). To initiate experiments, 16 h cultures of each
strain were standardized to an OD600 of 1.0. Strains were co-inoculated as a 100-fold dilution in 10 mL
of MRS media containing 20 g/L of either LNT, LNnT, 20 -FL or a combination of all three in equal
proportions (mixed HMO(mHMO)). Serial passages were performed every 24 h by diluting the culture
1:100, so that 0.1 mL of the medium with bacteria was transferred into a 10 mL of fresh medium
containing the same HMO. At each transfer, the cultures were first mixed by vortex for 30 seconds.
All incubations were performed at 37 ◦ C inside anaerobic chamber maintained at 5% H2 , 5% CO2 ,
and 90% N2 (Coy Laboratory Products, Grass Lake, MI, USA). Cells from 1.0 mL samples were collected
from the inoculum and at the end of each incubation period (24, 48 and 72 h) and frozen at −80 ◦ C.
To determine whether the initial inoculum influenced the observed relative fitness of H5-positive
strains and H5-negative strains, pairwise growth competition experiments were conducted in 96-well
plates. Briefly, 16 h liquid cultures of the competing strains were adjusted to an OD600 of 1.0 and
washed twice with RPMI medium (sans glucose). Adjusted cultures were then mixed at ratios of 1:1,
1:2 and 1:4 by volume (H5 positive to H5 negative). Mixtures were then used to inoculate 200 µL of
RPMI media containing 20 g/L of LNnT or 20 -FL as the sole carbon source. Plates were incubated
anaerobically at 37 ◦ C. The competition mixtures were maintained by 100-fold dilutions performed
every 24 h, for three cycles. After each cycle, cells from each well were spun down and pellets frozen at
−80 ◦ C.
Genomic DNA was extracted from the cell pellets using a KingFisher flex purification system
(ThermoFisher Scientific, Waltham, MA, USA), with reagents from the ZymoBIOMICS 96 MagBead
DNA kit (Zymo Research, Irvine, CA, USA). Standard curves were used for absolute quantification of
each strain using genomic DNA extracted from previously quantified cultures. Quantitative PCRs
were performed on a QuanStudio3 (ThermoFisher Scientific, Waltham, MA, USA). The reaction
mixture consisted of 0.5 µL of each primer (10 µM each), 5 µL of PerfeCTa Multiplex qPCR ToughMix
(QuantaBio, Beverly, MA, USA), 11.5 µL of water and 5 µL of template DNA. The PCR conditions
included 1 cycle of initial denaturation at 95 ◦ C for 3 min, followed by 40 cycles at 95 ◦ C for 15 s and
60 ◦ C for 1 min.
2.9. In Vivo Strain Competition Experiments
The relative fitness of the strains EVC001 and NLS in the ecological conditions of the breastfed
infant gut was determined over a period of 3 days in a proof-of-concept study. Two (one 5-day-old
male and one 3-day-old female) vaginally born, exclusively breastfed infants were fed half a serving
of the probiotic product containing the strain B. infantis EVC001 and a full serving of the probiotic
product containing the strain B. infantis NLS. Servings were determined as per the label instructions.
Fecal samples were collected one day prior and for three days after the infants were fed the strain
combination. DNA extraction and strain quantification were performed as described for the in vitro
tests. Total B. infantis was quantified using methods by Lawley et al. 2017 [26]. Competitive fitness
was defined as the proportion of each strain to the total B. infantis population calculated as the sum
of abundances of both strains in the stool samples. The protocol utilized in this case study (EV-8701)
was IRB approved. Informed consent was obtained from all study participants. The original protocol
was written to feed equivalent amounts of each strain, but due to commercial availability as well
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as concentration differences in the powdered probiotics, mothers ended up feeding the servings as
described above.
2.10. Statistical Analysis
Statistical tests were performed as described in figure legends using R v.3.6.2 or the software
GraphPad Prism v.7.0. Differences between groups were considered statistically significant when
p values were < 0.05.
2.11. Data Availability
The novel genome sequences of B. infantis strains sequenced in this study were deposited in NCBI
(https://www.ncbi.nlm.nih.gov/) under BioProject accession number PRJNA636403. Individual strains
accession numbers are listed in Table 1.
3. Results
3.1. General Genome Features of B. infantis Strains
In order to determine the genomic characteristics of distinct B. infantis strains, we sequenced and
closed the genomes of 12 isolates obtained from probiotic products targeted for pediatric populations
(Table 1). We performed a genome-wide comparative analysis including published B. infantis genomes.
When strain designation was not noted on the product label, probiotic isolates were assigned integer
numbers based on isolation order preceded by a PI_ for Probiotic Isolate. Same strains isolated from
different products are denoted by subscripts (x and y) (Table 1). To ensure uniformity in gene prediction,
all B. infantis genomes, including those retrieved from public databases, were annotated using Prokka
v1.12 [29]. The average genome coverage was 202× (min = 88×; max = 486×) (Table 1). The number
of predicted coding sequences ranged from 2227 for the B. infantis PI_002 to 2547 for the B. infantis
ATCC 15697 strains, respectively. The percentage G+C content was calculated to be an average of
59.38 ± 0.24%. The average genome size was 2659 ± 97.9 Kbp, with B. infantis EVC001 having the
largest genome (2832 Kbp) and NLS having the smallest (2598 Kbp). The genomes of ATCC 15697,
JCM 1222 and EVC001 were predicted to encode 84 tRNAs while the rest of the strains were predicted
to encode 59 (Table 1).
3.2. Comparative Genomic Analyses Revealed a High Degree of Genetic Conservation
The BLAST Ring Image Generator (BRIG) was used to graphically compare strains using the type
strain B. infantis ATCC 15697 as reference. As shown in Figure 1a, the chromosomal backbones of the
strains B. infantis EVC001 and JCM 1222 were congruent to the type strain. The remaining strains
had large regions of similarity (99%) to the type strain, interspersed with regions of dissimilarity and
gaps. Rings were ordered based on ANI scores against B. infantis ATCC 15697 in decreasing order from
inner (highest score) to outer (lowest score) rings, respectively (max > 0.99; min = 0.98; median = 0.98;
±SD = 0.005). The intensity of color in the figure reflects the percent similarity identity based on
BLASTn results against B. infantis ATCC 15697, from darker colors representing 100% similarity to
lighter colors representing a 70% minimum identity score. GC content and GC sk (+/−) are also
reported (Figure 1a).
Examination of the BRIG image and manual curation of genomes aligned using Progressive
Mauve [45] revealed gaps and regions of dissimilarity in the sequence alignments which were mainly
annotated as hypothetical proteins or mobile genetic elements, including bacteriophage-related proteins
and transposases. Particularly, the region between 1600 and 2100 kb contained three major gaps that
were classified as incomplete prophage using the PHAge Search Tool Enhanced Release (PHASTER),
2016 release [46]. The main area of gap between the 1370 and 1500 kb region was not classified
as prophage by PHASTER and thus manually curated and annotated. A total of 131 open reading
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frames were identified, of which only 18 were functionally annotated and included transposases,
transcriptional regulators, phage integrases and pseudogenes (Figure 1a).
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Genomes circles are ordered sequentially based on decreasing average nucleotide identity (ANI)
scores
S1) beginning withaverage
the genome of JCM
1222 (most inner blue
circle) and followed
by scores (Table S1) beginning
ordered sequentially based
on(Table
decreasing
nucleotide
identity
(ANI)
with the genome of JCM 1222 (most inner blue circle) and followed by EVC001, BB-02 (DSM 33361),
PI_004, PI_007, PI_009, PI_010, NLS, R0033x, PI_002, HA-116, R0033y, PI_008. Homology regions are
colored from lightest to darkest shade, respectively. Regions with less than 70% identity appear as blank
spaces in each ring. (b) Heat map displaying MLST phylogenetic relatedness and percent sequence
identity (determined by tBLASTn) of HMO utilization genes compared to the genome of B. infantis
ATCC 15697. The color of each tile of the heat map indicates the percent homology as indicated by the
key. Tiles representing the genes of each cluster are arranged sequentially but, for space constrains,
only every other Blon_ locus tag is shown.

Average nucleotide identity (ANI) was computed for all genomes and resulted in high percent
identity overall, with an average ANI of 99.274% (±SD 0.76%). Compared to the type strain, the average
ANI for all genomes was 98.79 (±SD 0.68%). Of the probiotic isolates, the genome closest to the ATCC
1567 was EVC001 with an ANI of 99.9%; and the most divergent was PI_008, with an ANI of 98.43%
(Table S1).
To identify shared and unique genes, we performed a pangenome analysis using Roary.
This analysis highlighted a high level of genome sequence similarity with a few putatively strain-specific
genes. The core pangenome consisted of 1621 open reading frames (ORFs). Notably, not all HMO
utilization genes were conserved, with notable divergence at the H5 gene cluster in all probiotic isolates
except for EVC001. The strain BB-02 (DSM 33361) was predicted to have 481 unique ORFs, of which the
majority were annotated as hypothetical proteins (80%). Of the remaining putatively unique genes with
a known functional annotation, the BLASTx analysis revealed only 19 genes with no homology to the
genome of the type strain. Of those, six were plasmid/phage related and another six had orthologues
in the ATCC 15697 or other probiotic B. infantis genomes. The remaining eight putatively unique genes
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to BB-02 (DSM 33361) are spread along the genome and are listed in Table S2. The strain with the
second most predicted unique genes was EVC001, having 10 unique ORFs annotated as hypothetical
proteins. The remaining strains were highly homogeneous but the strains PI_010, PI_009 and PI_006
were predicted to have three, two, and one unique ORF, respectively. One ORFs was predicted to be
unique to the strain R0033x but not found in R0033y, which is intriguing and suggests a sequencing
and/or assembly error given that the strains are the same but isolated from different products. Here, it
is worth mentioning that slightly different variations in the results on the reported ORFs are expected
every time a pangenome is computed, even when starting with the same input. This is due to the fact
that Roary uses a non-deterministic heuristic approach to reduce computational time (Page et al., 2015).
The remaining strains were not predicted to have any unique ORFs.
3.3. Phylogenetic Grouping Corresponds with Divergence in HMO Utilization Genes
Multi-locus sequence analysis was conducted to gain further insight into phylogenetic relatedness
of the strains. Visualization of the phylogenomic tree revealed a clear separation of the strains into
two distinct groups, with considerable genetic homogeneity within each group. Group 1 consisted of
B. infantis EVC001, and the type strain genomes, ATCC 15967 and JCM1222. The remaining isolates
formed a monophyletic clade (Group 2) with a remarkable degree of homogeneity between the genomes
(Figure 1b). These results corroborate the high degree of genome conservation, as suggested by the
pangenome and ANI analyses.
In B. infantis, genes related to HMO-utilization are organized in five clusters of genes (H1–H5) [14].
In order to determine the degree of conservation of these genes among strains, gene sequences were
compared to the type strain B. infantis ATCC 15697 using tBLASTn (Figure 1b). Genetic differences were
identified at the H1, H2 and H5 clusters. Specifically, the strain BB-02 (DSM 33361) was divergent from
the type strain at the H1 cluster in the F1SBP genes Blon_2352 (80.15% identity) and Blon_2331 (90.4%
identity). Furthermore, homologous sequences to the genes to Blon_0243 (a predicted transcriptional
regulatory protein), Blon_0244 (a predicted histidine kinase HisK), and Blon_0245 (a predicted MFS1
transmembrane protein) of the H2 cluster were not identified in the genome of BB-02 (DSM 33361).
The remaining Group 2 strains were divergent from the type strain at the H1 cluster genes Blon_2344,
Blon_2347 and Blon_2351 (85.26% identity, 88.89% identity and 90.65% identity, respectively). The most
consistent genomic divergence between strains in Group 1 and Group 2 occurred in the H5 cluster.
Specifically, in the genes Blon_2175, Blon_2176 to Blon_2177 encoding an ABC-type transporter
predicted to uptake lacto-N-biose (Figure 1b). Further examination, by aligning this genomic region in
representative strains from Group 1 (ATCC 15697 and EVC001) and Group 2 (NLS and BB-02(DSM
33361)) (Figure 2a), revealed that the genes Blon_2175, Blon_2176 and Blon_2177 are in fact absent from
the Group 2 strains (Figure 2a). This same region in the EVC001 and ATCC 15697 strains presented a
high degree of synteny and conserved gene organization. Mobile genetic elements including a phage
shock protein (Blon_2168) and transposon integrase (Blon_2181) were identified in the flanking regions
to the ABC transporter in Group 1 strains. (Figure 2a). The genomes of NLS and BB-02 (DSM 33361)
are predicted to encode genes homologous to Blon_2168 but not to Blon_2181 and possess an intact
anti-terminator, which is truncated by the integration of Blon_2181 in Group 1 strains (Figure 2a).
From these analyses, it can be concluded that the genomes of the analyzed B. infantis isolates display
three distinct genomic variants with respect to HMO utilization genes. Group 1 strains are replete
and possess the full gene repertoire of HMO-related genes (H5-positive genomic variant). Group 2
strains are all deplete of the ABC-type transporter of the H5 cluster (H5-negative genomic variant).
The third genomic variant is displayed in the strain of BB-02 (DSM 33361), which in addition to being
H5 negative is also deplete at the H2 cluster.
3.4. Divergence in the H5 Gene Cluster Is Associated with Poor Growth on HMOs
Probiotic strains were assessed for growth lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT),
These HMOs represent the major structural

or 20 -fucosyllactose (20 -FL) as the sole carbohydrate source.

Nutrients 2020, 12, 3247

10 of 22

classes of neutral non-fucosylated (LNT and LNnT) and fucosylated (20 -FL) HMOs in human milk.
At the 16 h time point, the mean OD600 of the H5-positive strain EVC00 on LNT (1.47 ± 0.03) and LNnT
(1.39 ± 0.05) was more than twice as high as the mean OD600 reached by any of the H5-negative strains.
Contrary to this trend, no major differences were observed between H5-positive and H5-negative
strains growing in 20 -FL, with all mean OD600 values below 0.65 (Figure 2b).
To determine growth on a broader array of HMO structures present in human milk, representative
strains from Group 1 (EVC001) and Group 2 (NLS) were grown on purified HMOs isolated from pooled
human breast milk. Strains were selected on the basis that they represent the two identified H5-positive
and H5-negative genomic variants of the H5 cluster and were available as single-strain probiotic
products, facilitating subsequent feeding trials. As shown in Figure 2c, the Group 1 strain EVC001,
which is H5 positive, reached significantly higher cell densities (p < 0.0001; two-way repeated-measures
ANOVA) than the H5-negative NLS strain (Figure 2c).
Because B. infantis has shown preferential consumption of smaller HMOs (degree of polymerization
[DP] < 7), and to further characterize phenotypic implications to the variations of the H5 cluster, growth
kinetics of select strains (EVC001 and NLS) grown on individual HMO standards was determined.
This analysis revealed HMO-specific variation in the growth capacity and overall growth kinetics
between strains. On LNT and LNnT, the H5-positive strain EVC001 attained significantly higher cell
densities, at a faster growth rate and producing a significantly larger area under the curve (Figure 3a,b).
The observed differences in growth were verified by glycoprofiling of the spent media, measuring
the percent of HMOs consumed by individual bacterial strains. EVC001 consumed 48.4 ± 4.7% and
49.1 ± 12.4% of LNT and LNnT, respectively. This is significantly more (p < 0.05; Wilcoxon rank-sum
test) than the percent consumption of NLS (15.2 ± 2.9% of LNT and 14.6 ± 4.11% LNnT). Notably,
low amounts of free N-acetylglucosamine (0.34 ± 0.11 mg/mL) were detected in the spent media of
NLS grown on LNT, which could be indicative of partial hydrolysis from lysed cells. Contrary to the
findings with LNT and LNnT, growth kinetics in 20 -FL were indistinguishable between strains and the
percent consumption of 20 -FL was comparable (44.7 ± 6.43% and 49.7 ± 5.23% for EVC001 and NLS,
respectively) (Figure 3c). Notably, growth in this substrate promoted a moderate growth (max OD600
(k) = 0.68 ± 0.02) at a slower growth rate ((r) = 0.34 h−1 ± 0.12) for EVC001 compared to the vigorous
growth on LNT (max OD600 = 1.3 ± 0.13; growth rate (r) 0.48 h−1 ± 0.17), and LNnT (max OD600 ± 0.09;
growth rate (r) 0.42 h−1 ± 0.06). Overall, these results indicate that the Group 2 NLS strain, which lacks
the ABC-type transporter genes of the H5 cluster, is significantly impaired, though not completely
abrogated for growth on LNT and LNnT. Furthermore, results showed that growth differences are
HMO specific, as the growth kinetics of both strains were congruent in 20 -FL.
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Figure 2. Alignment of a genomic region containing the H5 gene cluster and growth on purified
from pooled
human milk samples. (a) Genomic map of the H5 cluster and flanking of representative
HMOs from pooled human milk samples. (a) Genomic map of the H5 cluster and flanking of
Group 1 (EVC001) and Group 2 (NLS and BB-02) strains compared to type strain. Genes belonging
representative Group 1 (EVC001) and Group 2 (NLS and BB-02) strains compared to type strain.
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Figure 3. Growth on HMOs of select B. infantis strains. Growth kinetics and HMO consumption of
Figure 3. Growth on HMOs of select B. infantis strains. Growth kinetics and HMO consumption of B.
B. infantis EVC001 (H5 positive, Group 1) and B. infantis NLS (H5 negative, Group 2) in mMRS medium
infantis EVC001 (H5 positive, Group 1) and B. infantis NLS (H5 negative, Group 2) in mMRS medium
0 -FL) as the
containing
(a) lacto-N-tetraose
(LNT),(LNT),
(b) lacto-N-neotetraose
(LNnT),
or or
(c)(c)
20 -fucosyllactose
containing
(a) lacto-N-tetraose
(b) lacto-N-neotetraose
(LNnT),
2′-fucosyllactose (2
(2′-FL)
carbon source. Growth indicators were compared, with statistical significance determined by Student’s
t-test indicated with asterisks; ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.

3.5. Competitive Assays
A competitive co-inoculation model was used to investigate the relative contribution of the H5
ABC-transporter to the ability of strains to grow under competitive conditions. As shown in Figure 4a,
despite the starting inoculum containing comparable numbers of each strain (mean Log10 CFU/mL
for EVC001 = 8.76 ± 0.07, and for NLS = 8.90 ± 0.03), the H5-positive EVC001 strain attained higher
growth after the first passage in all three HMOs. The differences were, however, HMO-dependent.
In the media containing LNT and LNnT, after 72 h in competition, the H5-negative NLS strain was
completely outgrown by the H5-positive EVC001 (Figure 4a). In media containing 20 -FL, the strains
maintained comparable growth for the first 24 h (mean Log10 CFU/mL for EVC001 = 8.82 ± 0.088, and
for NLS = 8.12 ± 0.098). However, the trend favored EVC001 by the second passage, with the EVC001

Nutrients
FOR PEER REVIEW
Nutrients2020,
2020,12,
12,x3247

14
13of
of22
22

maintained populations of at least 107 and 108 on days 2 and 3 of competition, irrespective of the
reaching >The
10-fold
greater
the NLS
strain (mean
Log10 CFU/mL
for for
EVC001
= 8.83±
0.036,after
and 24
for
inoculum.
highest
cell over
numbers,
irrespective
of inoculum,
detected
the strain
HA-116
4
5
NLS
=
6.99
±
0.908).
By
the
third
passage
(72
h
in
competition),
the
mean
Log
difference
between
hours in competition with EVC001 were 3.39 × 10 CFU/mL on 2′-FL and 4.98 × 1010 CFU/mL on LNnT.
the strainsirrespective
had increased
to 5inoculum,
(mean Log
CFU/mL of
forthe
EVC001
= 9.53±were
0.07,detected
and for at
NLS
= 4.34 ±
Similarly,
of the
cell
strain PI_008
an average
10 numbers
0 -FL observed in competition (Figure 4a) was incongruent
0.18).
theon
growth
difference
of
3.42Intriguingly,
× 104 CFU/mL
2′-FL and
1.07 × in
1042on
LNnT, compared to the strain ECV001 which formed
with single-strain
growth
measurements
which suggested
strains
wereBoth
equally
equipped
populations
of at least
3.47
× 107 after 24(Figure
hours 3c),
in competition
with the
strains.
HA-116
and
to utilize
thisundetectable
HMO. Finally,
to the5a).
results
with the individual
HMOs,
when
all three
were
PI_008
were
by contrary
day 3 (Figure
Collectively,
these results
provide
further
evidence
combined
(mHMO),
thehave
differences
in growth
between
the strains
wereindicating
less prominent.
canH5
be
that
H5-negative
strains
a growth
impairment
on LNT
and LNnT,
absenceThis
of the
explained
bytransporter
the differences
hierarchicalmutation,
utilization
of resources
strains,
in whichwhen
EVC001
cluster
ABC
is aindeleterious
which
imposesofathe
fitness
detriment
in
shows preference
for LNT andstrains
LNnT,growing
and NLSon
shows
preference for 20 -FL (Figure 4b).
competition
with H5-positive
HMOs.

Figure4.
4. (a)
(a)In
Invitro
vitro competition
competitionexperiments
experimentsbetween
betweenthe
theB.
B.infantis
infantisstrains
strainsEVC001
EVC001and
andNLS
NLSin
inthe
the
Figure
HMO standards
standards lacto-N-tetraose
(LNnT),
20 -fucosyllactose
(20 -FL), or(2′an
HMO
lacto-N-tetraose(LNT),
(LNT),lacto-N-neotetraose
lacto-N-neotetraose
(LNnT),
or (c) 2′-fucosyllactose
equalorcombination
of all three (mixed
HMO (mixed
(mHMO)).
(b) Percent
consumption
of individual
HMO
FL),
an equal combination
of all three
HMO
(mHMO)).
(b) Percent
consumption
of
standards by
B. infantis
EVC001
and
B. infantis
NLS and
during
growth on
mHMO.
significance
individual
HMO
standards
by B.
infantis
EVC001
B. infantis
NLS
duringStatistical
growth on
mHMO.
of
strains
in
competition
was
determined
by
two-way
repeated-measures
ANOVA
with
Holm–Sidak
Statistical significance of strains in competition was determined by two-way repeated-measures
multiple comparison
adjustment.
Significant
differences
in percent
consumption
were determined
by
ANOVA
with Holm–Sidak
multiple
comparison
adjustment.
Significant
differences
in percent
Student’s t-test.
consumption
were determined by Student’s t-test.

Co-inoculation
competition
experiments
withrelevance
varying instrain
ratios
in the ainoculum,
To
test whether the
results observed
in vitro had
vivo, we
performed
proof-ofwere
performed
to
determine
whether
the
starting
inoculum
had
an
impact
on
the
observed
ecological
concept trial by feeding EVC001 and NLS to two breastfed infants and calculated the relative
fitness of strains,
well asrecovered
to determine
if the
fitness
disadvantage
observed for NLS
wasover
true for
other
proportion
of theasstrains
from
stool
samples
using a strain-specific
qPCR
a 3-day
0 -FL, as these were the HMOs for which
H5-negative
strains.
For
this
experiment,
we
choose
LNnT
and
2
period (Figure 5b). By day 3, the total counts of total B. infantis were 5 × 1010 and 2.1 × 109 CFU per µg
thestool
growth
differences
EVC001
and NLS
hadindicates
been most
prominent
and most
of
DNA
in infantbetween
A and B,
respectively.
This
that
the B. infantis
can comparable,
abundantly

Nutrients 2020, 12, 3247

14 of 22

respectively. Mixtures were prepared at 1:1, 1:2, and 1:4 ratios, favoring the H5-negative strain. Results
from this experiment show that the initial inoculum did not alter the observed competitive fitness of
strains. Specifically, the H5-positive EVC001 outcompeted all three H5-negative strains (NLS, HA-116
and PI_008) by the third day of competition despite being at a numerical disadvantage in the inocula.
These competitive dynamics do not appear to be strain or HMO-specific. As shown in Figure 5a, all
H5-negative strains were detected 24 h after the initial inoculation but were eventually outcompeted
by the second or third day of competition. The only exception to this trend was for the strain HA-116,
which became undetected after 24 h in competition when inoculated 1:2 with EVC001. Furthermore,
following the trend observed in the previous competition experiments using larger volumes, the strain
NLS appeared to be more adept at competing for growth with EVC001 on 20 -FL. This is evidenced
by the close cell counts (CFU/mL) between EVC001 and NLS by 24 h in this media. Specifically, 24 h
after the strains were inoculated at a 1:1 ratio, the cell numbers were on average 3.0 × 107 CFU/mL for
EVC001 and 8.24 × 106 CFU/mL for NLS, Similarly, after the inoculum at the 1:2 ratio, cell numbers
were 2.23 × 107 CFU/mL for EVC001 and 2.87 × 107 CFU/mL for NLS. Finally, for the inoculum at the
1:4 ratio, at the 24 h time point, the detected cell numbers for the NLS strain were almost twice as much
(3.76 × 107 CFU/mL compared to 2.26 × 107 CFU/mL) as EVC001. However, on the second day of the
competition growth experiment in 20 -FL (48 h after initial inoculum), cells numbers for the NLS strain
were considerably less, on average, when compared to EVC001, 2.26 × 108 CFU/mL (NLS) vs. 5.18
× 104 CFU/mL (EVC001) for the 1:1 inoculum; 2.60 × 108 CFU/mL vs. 9.43 × 104 CFU/mL for the 1:2
inoculum; and 2.43 × 108 CFU/mL vs. 3.13 × 105 CFU/mL for 1:4 inoculum. By day 3, the NLS became
undetectable by qPCR in this media. Similar dynamics were not observed in LNnT, where the highest
cell numbers for NLS after 24 h in competition were on average 6.19 × 105 CFU/mL 24 h after the initial
1:4 inoculum compared to 2.48 × 109 CFU/mL for EVC001. By the second day in competition for LNnT,
the NLS strain was no longer detected in the media while EVC001 maintained populations of at least
107 and 108 on days 2 and 3 of competition, irrespective of the inoculum. The highest cell numbers,
irrespective of inoculum, detected for the strain HA-116 after 24 h in competition with EVC001 were
3.39 × 104 CFU/mL on 20 -FL and 4.98 × 105 CFU/mL on LNnT. Similarly, irrespective of the inoculum,
cell numbers of the strain PI_008 were detected at an average of 3.42 × 104 CFU/mL on 20 -FL and 1.07
× 104 on LNnT, compared to the strain ECV001 which formed populations of at least 3.47 × 107 after 24
h in competition with the strains. Both HA-116 and PI_008 were undetectable by day 3 (Figure 5a).
Collectively, these results provide further evidence that H5-negative strains have a growth impairment
on LNT and LNnT, indicating absence of the H5 cluster ABC transporter is a deleterious mutation,
which imposes a fitness detriment when in competition with H5-positive strains growing on HMOs.
To test whether the results observed in vitro had relevance in vivo, we performed a proof-of-concept
trial by feeding EVC001 and NLS to two breastfed infants and calculated the relative proportion of
the strains recovered from stool samples using a strain-specific qPCR over a 3-day period (Figure 5b).
By day 3, the total counts of total B. infantis were 5 × 1010 and 2.1 × 109 CFU per µg of stool DNA in
infant A and B, respectively. This indicates that the B. infantis can abundantly colonize and thrive in
conditions of the infant, which is in line with previous feeding trials of the strain B. infantis EVC001 [21].
As shown in Figure 5b, neither strain was detected in stools collected prior to feeding B. infantis.
After feeding the strains and over the 3-day sampling period, the proportions of each strain in the stool
samples were considerably different, with the H5-negative strain NLS making up a small proportion of
the B. infantis population in comparison to the H5-positive strain EVC001 (Figure 5b). These results,
although limited in sample size, when coupled with the in vitro data, suggest that genotypic differences
of ABC-type transporter in the H5 cluster may represent a fitness cost on the ability of strains to
compete for HMOs in the infant gut.
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Figure 5. In vitro competition experiments and strain fitness in the breastfed infant gut. (a) In vitro
growth experiments with varying rations of H5-negative to H5-positive strains in the inocula.
Data represents the mean CFU/mL from three replicates. (b) Relative fitness (determined as proportion)
of B. infantis NLS and B. infantis EVC001 in the fecal samples of two exclusively breastfed infants (A and
B) before (day zero) and for three days after feeding the probiotic strains. For data analysis, if threshold
cycle values were below detection limit, the bacterial abundance was recorded as the lowest dilution in
1
the standard curve.

4. Discussion
The beneficial effects provided by B. infantis are attributed to its adaptation to colonizing the infant
gut, which is mediated by the presence of specialized ABC transporters to capture and internalize
HMOs [12]. Additionally, the overrepresentation of low-molecular-weight glycans that comprise breast
milk HMOs and the corresponding preferential consumption of these glycans by B. infantis has long
been speculated to be the result of a tripartite coevolutionary relationship between the mother’s milk,
the infant, and B. infantis [13,47–49]. However, due to limited genetic tools for B. infantis, the traditional
experimental validation of these hypotheses has been limited. In this study, we carried out a functional
genomics approach to gain a mechanistic understanding of the metabolism of HMOs by B. infantis
strains. We focused on the metabolism of neutral low-molecular-weight type-1 (LNT) and type-2
(LNnT) glycans as well as 20 -FL which are abundant in most human milk. We then conducted a small
(n = 2) proof-of-concept trial aimed to test whether the findings in vitro could also be observed in the
breastfed infant gut.
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Analysis of the intra-species genomic diversity of twelve B. infantis strains isolated from
commercial probiotic products revealed the genetic variability among strains, most of which consisted
of hypothetical genes and mobile genetic elements. As previously reported [16], strain-level genetic
variations were mainly located in genes predicted to be involved in the uptake of HMOs, particularly
the Blon_2175-2177 ABC transport system located in the H5 cluster [16]. The Blon_2175-2177
ABC-transporter is predicted to bind core type-1 glycans (i.e., LNT) [50]. However, the relative gene
expression of the solute binding protein Blon_2177 increases in the presence of LNT and LNnT [50,51]
(Figure S1), which may suggest that is active on both type-1 and type-2 HMOs. Our results confirm and
extend previous literature as we demonstrated that H5-negative strains, which lack the ABC transport
system located in the H5 cluster, exhibited impaired growth when LNT, LNnT and pooled HMOs
were provided as the sole carbon source (Figures 2–5). Our results also indicated that the predicted
inability of H5-negative strains to access these HMOs is associated with functional deficiencies in vitro.
Furthermore, according to our preliminary in vivo data, respective to H5-positive strains, H5-negative
strains are impaired in their ability to colonize the infant gut, which could have an impact on benefits
imparted to the infant host. This highlights the importance of strain for the selection of probiotics
for human milk-fed infants. However, appropriately controlled and powered trials are necessary to
confirm this hypothesis. Future studies are also warranted to explore the effects of the oligosaccharide
composition in human milk with respect to the colonization of B. infantis strains as well as compare the
overall effects on the microbiome in infants fed H5-positive and H-5 negative strains.
The analyzed genomes of B. infantis encode numerous mobile genetic elements, suggesting the
lateral acquisition of genetic material [14] (Figures 1a and 2a). Horizontal gene transfer has long been
recognized as an important force in the evolution of bacteria [52]. Changes to the genome by gene
acquisition and deletion can confer selective advantages including the evolution of complex symbiotic
traits [53] and host-specific adaptations [54,55]. Typically, horizontally acquired genetic regions are
inserted near tRNA genes and are flanked by regions containing mobile elements such as phage related
genes and transposases [52]. The presence of various phage-related sequences regions neighboring
Blon_2175-2177 indicate that horizontal transfer events may have shaped this locus, as it has been
detected in other regions of the genome of the type strain B. infantis ATCC 15697 [14]. However,
the absence of intact prophage genes suggests that the integration did not occur recently. Moreover,
the H5 cluster is the only HMO-related cluster conserved in members of three B. longum subspecies
(B. longum longum, B. longum infantis and B. longum suis), providing further indication of an ancient
HGT event, possibly predating the separation of the subspecies [16]. Thus, analysis of the H5 cluster in
strains of these subspecies may provide insight into the events that have shaped the evolution of this
genomic region.
It remains unknown how a lineage of B. infantis strains lacking the Blon_2175-2177 ABC transporter
emerged, and whether populations of this lineage are maintained naturally among infants. Our analysis
was performed in strains isolated from probiotics, which given the high degree of genetic conservation
are likely the same (individual) strain, distributed by various manufacturers, as has been reported for
other probiotic bifidobacteria [34,56]. Further, although others have found similar genotypes in strains
isolated from infant feces [16], it is possible for these strains to have originated from ingested probiotic
products, as our own efforts to isolate B. infantis strains from control infants (not fed a B. infantis
probiotic) from a previous clinical study in the US [21] were unsuccessful, but it agrees with results
from other resource-rich countries where B. infantis is now absent [57]. This would suggest that the
absence of the Blon_2175-2177 ABC transporter may be an artifact of the history of probiotic strains,
which are known to be prone to phage infection and genome decay during production [58]. However,
further experiments with a larger number of both probiotic-isolated and extant infant-derived strains
will be required to evaluate this hypothesis. Finally, it has been argued that the amount and type of
glycan fucosylation in breast milk and, in particular, the abundance of 20 -fucosyllation, directly impacts
the colonization dynamics of bifidobacteria in infants from resource-rich geographical regions [58,59].
All strains characterized in this study encoded the complete set of genes predicted for 20 -FL transport
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(Blon_0341-0334 and Blon_2202-2204) [49]. Accordingly, the growth kinetics of the NLS strain during
in vitro growth in 20 -FL remained very close to that of EVC001, indicating that both strains are similarly
equipped to access this glycan (if present) in the breastfed infant gut; however, observed cell densities
and growth rates were substantially lower during growth on 20 -FL than on LNT and LNnT (Figure 3),
likely because fucose is not utilized by Bifidobacterium as a carbon source but rather metabolized
into pyruvate and 1,2 propanediol [60]. This supports our previous observation that secretor status
(i.e., FUT2 alleles) did not impact colonization by B. infantis EVC001 (Frese et al. 2017). Thus, 20 -FL
may not be a critical substrate for B. infantis growth in the infant gut, relative neutral non-fucosylated
to type-1 and type-2 HMOs, although 2’-FL might be relevant for interspecies syntrophic interactions
within the microbiome [61]. Together, these findings indicate that LNT and LNnT are preferred
substrates over 20 -FL for B. infantis strains whose genomes are replete with the full repertoire of HMO
utilization genes.
While previous studies had predicted the role of the Blon_2175-2177 ABC transport system [50,51],
results presented in this study specifically provide a mechanistic assessment of the role of this ABC
transport system in the consumption of HMOs and in the colonization of the breastfed infant gut.
Our results showed that the HMO consumption behavior of B. infantis is consistent with the functional
ability inferred by the genomic analyses. The absence of this particular ABC transport system
corresponded with impaired growth on LNT, LNnT and pooled HMOs from breast milk samples. LNT,
LNnT and small (DP < 7) type-1 and type-2 HMOs are highly predominant in breast milk and are
produced consistently throughout the lactation period [7]. Thus, the ability to access these glycans
could be a major determinant in a strain’s competitive success in the breastfed infant gut.
Although our results strongly associate the Blon_2175-2177 ABC transport system with mediating
the metabolism of LNT and LNnT, given that there is limited consumption of these HMOs by NLS
(which lacks Blon_2175-2177), we cannot rule out the possibility that other less-efficient transporters
located elsewhere in the genome participate in the uptake of these glycans. In fact, there are overlapping
transcriptional signals and the expression of ABC permeases located outside the H5 cluster occur during
growth on both LNT and LNnT, suggesting that the isomers are metabolized through overlapping
pathways [50,51]. Additionally, although extracellular degradation of HMOs has not been described
for B. infantis, the presence of trace amounts of intermediate monosaccharides in the spent media of the
NLS strain could indicate partial degradation of LNT and LNnT, or the release of functional enzymes
following cell lysis [19]. Further, the comparative genomics approach used in this study facilitated
the explanation of differences previously observed in the HMO utilization phenotype of a number of
B. infantis strains [50,51].
It is important to point out that while our results support a connection between a genomic variant
and a fitness phenotype both in vitro and in vivo, our work is limited in that it cannot provide definitive
conclusions to the substrate specificity of the H5 cluster ABC-type transporter. Significant progress
has been made in the development of molecular tools for bifidobacteria [49]. Thus, future work
undertaking loss of function gene knockout recovered through complementation will be required
to derive definitive conclusions. Furthermore, although our in vivo results were consistent and in
agreement with the in vitro findings, the competition experiments in breastfed infants are limited.
Future, larger and well-powered studies are required to confirm the hypotheses generated in this study.
5. Conclusions
Given the importance of early life microbiome assembly for long-term health, and the role that
B. infantis plays in providing key ecosystem services to the infant [62], there is a growing interest
in the development of probiotic products containing B. infantis. Based on results presented here,
we predict that strain-specific differences in the functional ability of B. infantis probiotics will also
manifest in the colonization of the infant gut. These differences may have implications for benefits
observed in human clinical studies linked to the high fitness of B. infantis EVC001, and the closely
related ATCC 15697, in term and preterm infants [5,21,62–66]. In fact, the apparent lack of major
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functional differences between EVC001 and ATCC 15697 suggests that these strains share many
phenotypic and health-promoting features related to the ability to metabolize HMOs and colonize
the infant gut. Thus, our work provides important insights into the understanding of the symbiotic
relationship between nursing infants and bifibacteria as well as key information regarding the ecology
of B. infantis. This information may aid in the selection of strains and ingredients for probiotic and
synbiotic formulations to support optimal modulation of the infant gut microbiome for the mitigation
of risk for acute dysbiosis-related diseases such as NEC and, in the long term, risks associated with
autoimmune disease development. In conclusion, our study highlights the importance of considering
genotypic variations and functional properties of probiotics strains as potentially critical determinants
of performance and fitness under the ecological conditions to which they are exposed.
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